Open AccessSafety and Tolerability of Topotecan-Eluting Radiopaque Microspheres for Hepatic Chemoembolization in a Rabbit Preclinical Model
Author(s) -
Andrew S. Mikhail,
Elliot Levy,
Venkatesh Krishnasamy,
David L. Woods,
J. Esparza-Trujillo,
Ivane Bakhutashvili,
Filip Banovac,
Paul Wakim,
Ayele H. Negussie,
Yiqing Tang,
Alexander Henman,
S. Willis,
John W. Karanian,
William F. Pritchard,
Andrew L. Lewis,
Bradford J. Wood
Publication year - 2020
Publication title -
cardiovascular radiology/cardiovascular and interventional radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 83
eISSN - 0342-7196
pISSN - 0174-1551
DOI - 10.1007/s00270-020-02609-z
Subject(s) - medicine , topotecan , tolerability , camptothecin , embolization , irinotecan , pharmacology , pharmacokinetics , in vivo , gastroenterology , urology , surgery , colorectal cancer , chemotherapy , cancer , adverse effect , chemistry , organic chemistry , microbiology and biotechnology , biology
Topotecan is a camptothecin analogue with potential advantages over irinotecan for transarterial chemoembolization (TACE) of hepatic colorectal metastases including greater anti-neoplastic activity without enzymatic activation. The purpose of this study was to assess safety and tolerability of topotecan-loaded radiopaque microspheres (ROMTOP) administered by TACE in a rabbit model and to compare the in vitro elution of topotecan from microspheres to irinotecan.